{"id":56535,"date":"2026-02-06T21:51:26","date_gmt":"2026-02-06T13:51:26","guid":{"rendered":"https:\/\/flcube.com\/?p=56535"},"modified":"2026-02-06T21:51:27","modified_gmt":"2026-02-06T13:51:27","slug":"hightide-therapeutics-reports-positive-phase-iib-centricity-data-for-htd1801-in-mash-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56535","title":{"rendered":"HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients"},"content":{"rendered":"\n<p><strong>HighTide Therapeutics Inc.<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/2511:HKG\">HKG: 2511<\/a><\/strong>), the China\u2011based biopharmaceutical company, announced <strong>completion of the Phase IIb CENTRICITY study<\/strong> evaluating <strong>HTD1801<\/strong> in patients with <strong>metabolic dysfunction\u2011associated steatohepatitis (MASH)<\/strong>, demonstrating therapeutic improvement trends across multiple liver histological endpoints versus placebo.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-milestone\">Clinical Trial Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study<\/strong><\/td><td>CENTRICITY \u2013 Phase IIb randomized, double\u2011blind, placebo\u2011controlled<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>HTD1801 (oral, first\u2011in\u2011class)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Metabolic dysfunction\u2011associated steatohepatitis (MASH)<\/td><\/tr><tr><td><strong>Primary Outcome<\/strong><\/td><td>Improvement trend across multiple liver histological endpoints vs. placebo<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Study completed; data readout announced<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Classification:<\/strong> <strong>First\u2011in\u2011class oral anti\u2011inflammatory and metabolic modulator (AIMM)<\/strong><\/li>\n\n\n\n<li><strong>Novelty:<\/strong> Globally first new molecular entity targeting <strong>cardiorenal metabolic (CKM) system diseases<\/strong><\/li>\n\n\n\n<li><strong>Dual\u2011Mechanism Design:<\/strong><\/li>\n\n\n\n<li><strong>AMPK activation<\/strong> \u2013 Enhances cellular energy metabolism and insulin sensitivity<\/li>\n\n\n\n<li><strong>NLRP3 inflammasome inhibition<\/strong> \u2013 Reduces inflammatory cytokine production and fibrosis progression<\/li>\n\n\n\n<li><strong>Synergistic Effect:<\/strong> Complementary pathways address both metabolic dysfunction and inflammatory damage, core drivers of MASH pathogenesis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-summary\">Clinical Evidence Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint Category<\/th><th>HTD1801 Performance vs. Placebo<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Liver Histology<\/strong><\/td><td>Improvement trend observed<\/td><td>NASH resolution and fibrosis reduction potential<\/td><\/tr><tr><td><strong>Metabolic Parameters<\/strong><\/td><td>AIMM mechanism suggests systemic metabolic benefit<\/td><td>CKM syndrome management beyond liver<\/td><\/tr><tr><td><strong>Anti\u2011Inflammatory Activity<\/strong><\/td><td>NLRP3 inhibition demonstrated<\/td><td>Addresses inflammatory component of MASH progression<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>Note: Full statistical results and specific histological responder rates pending peer\u2011review publication and regulatory disclosure.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-context\">Strategic Positioning &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MASH Market Opportunity:<\/strong> The global MASH (formerly NASH) therapeutics market is projected to exceed <strong>$20 billion by 2030<\/strong>, with only limited approved options currently available\u2014creating first\u2011mover advantage window for novel mechanisms.<\/li>\n\n\n\n<li><strong>CKM System Play:<\/strong> HTD1801\u2019s positioning as a <strong>cardiorenal metabolic modulator<\/strong> expands addressable market beyond MASH to include <strong>type 2 diabetes, chronic kidney disease, and cardiovascular risk<\/strong>\u2014diseases sharing metabolic\u2011inflammatory pathophysiology.<\/li>\n\n\n\n<li><strong>Differentiation Factor:<\/strong> Unlike single\u2011target competitors (e.g., THR\u2011\u03b2 agonists, FXR modulators), HTD1801\u2019s <strong>dual AMPK\/NLRP3 mechanism<\/strong> offers potential for superior efficacy in metabolic\u2011inflammatory comorbidities and reduced fibrosis progression.<\/li>\n\n\n\n<li><strong>China\u2011Global Hybrid:<\/strong> HighTide\u2019s Hong Kong listing (<strong>2511.HK<\/strong>) and first\u2011in\u2011class asset position the company for <strong>international partnership or licensing<\/strong> as MASH assets command premium valuations in Western markets.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-pipeline-amp-next-steps\">Development Pipeline &amp; Next Steps<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activity<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Completed<\/strong><\/td><td>Phase IIb CENTRICITY (MASH)<\/td><td>Q1 2026 data readout<\/td><\/tr><tr><td><strong>Next<\/strong><\/td><td>Phase III MASH registration trial design<\/td><td>Initiation anticipated 2026<\/td><\/tr><tr><td><strong>Parallel<\/strong><\/td><td>CKM expansion studies (diabetes, CKD)<\/td><td>Pipeline prioritization pending<\/td><\/tr><tr><td><strong>Regulatory<\/strong><\/td><td>FDA\/EMA pre\u2011submission meetings<\/td><td>2026 planning<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding HTD1801 clinical development, regulatory pathways, and commercial potential in MASH and CKM indications. Actual results may differ due to Phase III trial outcomes, competitive dynamics in the MASH market, and regulatory review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020501165_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026020501165_c.\"><\/object><a id=\"wp-block-file--media-0227d3fa-17a8-46fe-a20b-a8b3f7f956cd\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020501165_c.pdf\">2026020501165_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020501165_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0227d3fa-17a8-46fe-a20b-a8b3f7f956cd\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HighTide Therapeutics Inc. (HKG: 2511), the China\u2011based biopharmaceutical company, announced completion of the Phase IIb&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,610,1309,76],"class_list":["post-56535","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hightide-therapeutics","tag-hkg-2511","tag-nash"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HighTide Therapeutics Inc. (HKG: 2511), the China\u2011based biopharmaceutical company, announced completion of the Phase IIb CENTRICITY study evaluating HTD1801 in patients with metabolic dysfunction\u2011associated steatohepatitis (MASH), demonstrating therapeutic improvement trends across multiple liver histological endpoints versus placebo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56535\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients\" \/>\n<meta property=\"og:description\" content=\"HighTide Therapeutics Inc. (HKG: 2511), the China\u2011based biopharmaceutical company, announced completion of the Phase IIb CENTRICITY study evaluating HTD1801 in patients with metabolic dysfunction\u2011associated steatohepatitis (MASH), demonstrating therapeutic improvement trends across multiple liver histological endpoints versus placebo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56535\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T13:51:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T13:51:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56535#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56535\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients\",\"datePublished\":\"2026-02-06T13:51:26+00:00\",\"dateModified\":\"2026-02-06T13:51:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56535\"},\"wordCount\":443,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"HighTide Therapeutics\",\"HKG: 2511\",\"NASH\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56535#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56535\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56535\",\"name\":\"HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-06T13:51:26+00:00\",\"dateModified\":\"2026-02-06T13:51:27+00:00\",\"description\":\"HighTide Therapeutics Inc. (HKG: 2511), the China\u2011based biopharmaceutical company, announced completion of the Phase IIb CENTRICITY study evaluating HTD1801 in patients with metabolic dysfunction\u2011associated steatohepatitis (MASH), demonstrating therapeutic improvement trends across multiple liver histological endpoints versus placebo.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56535#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56535\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56535#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients - Insight, China&#039;s Pharmaceutical Industry","description":"HighTide Therapeutics Inc. (HKG: 2511), the China\u2011based biopharmaceutical company, announced completion of the Phase IIb CENTRICITY study evaluating HTD1801 in patients with metabolic dysfunction\u2011associated steatohepatitis (MASH), demonstrating therapeutic improvement trends across multiple liver histological endpoints versus placebo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56535","og_locale":"en_US","og_type":"article","og_title":"HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients","og_description":"HighTide Therapeutics Inc. (HKG: 2511), the China\u2011based biopharmaceutical company, announced completion of the Phase IIb CENTRICITY study evaluating HTD1801 in patients with metabolic dysfunction\u2011associated steatohepatitis (MASH), demonstrating therapeutic improvement trends across multiple liver histological endpoints versus placebo.","og_url":"https:\/\/flcube.com\/?p=56535","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-06T13:51:26+00:00","article_modified_time":"2026-02-06T13:51:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56535#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56535"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients","datePublished":"2026-02-06T13:51:26+00:00","dateModified":"2026-02-06T13:51:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56535"},"wordCount":443,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","HighTide Therapeutics","HKG: 2511","NASH"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56535#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56535","url":"https:\/\/flcube.com\/?p=56535","name":"HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-06T13:51:26+00:00","dateModified":"2026-02-06T13:51:27+00:00","description":"HighTide Therapeutics Inc. (HKG: 2511), the China\u2011based biopharmaceutical company, announced completion of the Phase IIb CENTRICITY study evaluating HTD1801 in patients with metabolic dysfunction\u2011associated steatohepatitis (MASH), demonstrating therapeutic improvement trends across multiple liver histological endpoints versus placebo.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56535#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56535"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56535#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56535"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56535\/revisions"}],"predecessor-version":[{"id":56537,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56535\/revisions\/56537"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}